Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
24 Cards in this Set
- Front
- Back
- 3rd side (hint)
|
Heparin |
Anticoagulant MA: binds to antithrombin and increases its activity. Inhibits 10a. Short half life (1-2hrs). Obtained from pigs, cows, sheep. Parenteral drug should be monitored for PTT. Adverse effect-HIT (heparin induced thrombocytopenia). |
|
|
|
Enoxaparin |
Low-molecular weight heparin. More predictable anticoagulation response. Subcutaneous |
|
|
|
Dalteparin |
Low-molecular weight heparin. |
|
|
|
Protamine sulfate |
Antidote for heparin |
|
|
|
Warfarin |
Anticoagulant MA: Inhibits production of vitamin K dependent factors 2,7, 9,10 by inhibiting vitamin K. Vitamin K competitive antagonist. PO drug should be monitored for PT-INR. |
|
|
|
Vitamin K |
Antidote for Warfarin |
|
|
|
Foundaparinux |
Anticoagulant MA: inhibit 10a. Less risk for HIT. Subcutaneous. |
|
|
|
Aspirin |
Antiplatelet drug MA: inhibits Coх irreversibly that inhibits TxA2 (responsible for vasoconstriction and platelet aggregation). Result-vasodialation and inability of platelets to aggregate. |
|
|
|
Dihydradamole |
Antiplatelet drug ADP reuptake inhibitor. Prevents release of ADP which is responsible for platelet aggregation and generation of TxA2. |
Watch for p d. |
|
|
Clopidogrel |
Antiplatelet drugs ADP inhibitor (ADP receptor blocker) inhibits ADP irreversibly. ADP is responsible for platelet aggregation and production of AxA2. |
Watch for p. d. |
|
|
Ticlopedin |
Antiplatelet drug MA: ADP inhibitor (inhibition of Tx2a and inhibition of platelet aggregation). |
|
|
|
Tirofiban |
antiplatelet drug New class GP 2b3a inhibitor Ma: block located on platelets glycoprotein receptors for fibrinogen and Von Willebrand factors. Without binding to them fibrin clot can’t be formed |
+ Watch for B A letters |
|
|
Eptifibatide |
Antiplatelet drug New class GP2b3a inhibitor |
Watch for b a letters |
|
|
Aminocapronic acid |
Antifibrinolytic drug Ma: inhibits the breakdown of clots |
|
|
|
Aminocapronic acid |
Antifibrinolytic drug Ma: inhibits the breakdown of clots |
|
|
|
Desmopressin |
Antifibrinolytic drug Ma: increases Von Willebrand (factor 8) and platelet aggregation that forms clots. Helpful with diabetes insipidus Analogue of ADH
|
|
|
|
Aminocapronic acid |
Antifibrinolytic drug Ma: inhibits the breakdown of clots |
|
|
|
Desmopressin |
Antifibrinolytic drug Ma: increases Von Willebrand (factor 8) and platelet aggregation that forms clots. Helpful with diabetes insipidus Analogue of ADH
|
|
|
|
Streptokinase |
Thrombolytic drug (older) Ma: activate fibrinolytic system: plasminogen-plasmin- lyse of clot. Derived from beta -hemolytic streptococci. |
|
|
|
Urokinase |
Thrombolytic drug (older) Ma: activation of fibrinolytic system (mainly plasminogen): plasminogen-plasmin- lyse of clot Naturally occurring human plasminogen activator |
|
|
|
Alteplase |
TPA (tissue plasminogen activator) Ma: activates fibrinolytic system New drug |
|
|
|
Anistreplase (APSAC) |
Thrombolytic drug (new t-PA) Anisoylated plasminogen streptokinase activator complex |
Suffix Ase |
|
|
Reteplase |
Thrombolytic drug New t-PA |
|
|
|
Tenecteplase |
Thrombolytic drug New t-PA |
|
